MDMX (MDM4), a Promising Target for P53 Reactivation Therapy and Beyond

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2016 Jul 3

PMID 27371671

Citations 24

Authors

Jean-Christophe Marine

Aart G Jochemsen

Affiliations

Soon will be listed here.

Abstract

The MDMX protein was identified as a p53-interacting protein with a strong similarity to MDM2. Like Mdm2, Mdmx expression is essential for curbing p53 activity during embryonic development, indicating nonredundant functions of Mdmx and Mdm2. There is now a large body of evidence indicating that cancers frequently up-regulate MDMX expression as a means to dampen p53 tumor-suppressor function. Importantly, MDMX also shows p53-independent oncogenic functions. These data make MDMX an attractive therapeutic target for cancer therapy. Here, we summarize the mechanisms used by cancer cells to increase MDMX expression and promising pharmacological strategies to target MDMX in cancer-in particular, the recent findings that antisense oligonucleotides (ASOs) can be used to efficiently modulate MDMX messenger RNA (mRNA) splicing.

Citing Articles

An Anti-Invasive Role for Mdmx through the RhoA GTPase under the Control of the NEDD8 Pathway.

Bou Malhab L, Schmidt S, Fagotto-Kaufmann C, Pion E, Gadea G, Roux P Cells. 2024; 13(19.

PMID: 39404389 PMC: 11475522. DOI: 10.3390/cells13191625.

Long-Read MDM4 Sequencing Reveals Aberrant Isoform Landscape in Metastatic Melanomas.

Patrick N, Markey M Int J Mol Sci. 2024; 25(17).

PMID: 39273363 PMC: 11395681. DOI: 10.3390/ijms25179415.

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector.

Lin W, Yan Y, Huang Q, Zheng D Biologics. 2024; 18:61-78.

PMID: 38318098 PMC: 10839028. DOI: 10.2147/BTT.S436629.

MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.

Liu J, Yang J, Pan Q, Wang X, Wang X, Chen H Eur J Med Res. 2024; 29(1):79.

PMID: 38281029 PMC: 10821240. DOI: 10.1186/s40001-024-01684-z.

Cellular carcinogenesis in preleukemic conditions:drivers and defenses.

Ueda K, Ikeda K Fukushima J Med Sci. 2023; 70(1):11-24.

PMID: 37952978 PMC: 10867434. DOI: 10.5387/fms.2023-17.

References

Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S . High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2015; 6(14):12654-67. PMC: 4494964. DOI: 10.18632/oncotarget.3705. View

Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H . USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer. 2015; 88(3):239-45. DOI: 10.1016/j.lungcan.2015.02.019. View

Xiong S, Van Pelt C, Elizondo-Fraire A, Liu G, Lozano G . Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006; 103(9):3226-31. PMC: 1413885. DOI: 10.1073/pnas.0508500103. View

Gilkes D, Pan Y, Coppola D, Yeatman T, Reuther G, Chen J . Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol. 2008; 28(6):1999-2010. PMC: 2268405. DOI: 10.1128/MCB.01633-07. View

Perez-Ortin J, Alepuz P, Chavez S, Choder M . Eukaryotic mRNA decay: methodologies, pathways, and links to other stages of gene expression. J Mol Biol. 2013; 425(20):3750-75. DOI: 10.1016/j.jmb.2013.02.029. View

Boutz P, Bhutkar A, Sharp P . Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev. 2015; 29(1):63-80. PMC: 4281565. DOI: 10.1101/gad.247361.114. View

Lebron C, Chen L, Gilkes D, Chen J . Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006; 25(6):1196-206. PMC: 1422166. DOI: 10.1038/sj.emboj.7601032. View

Chen L, Borcherds W, Wu S, Becker A, Schonbrunn E, Daughdrill G . Autoinhibition of MDMX by intramolecular p53 mimicry. Proc Natl Acad Sci U S A. 2015; 112(15):4624-9. PMC: 4403185. DOI: 10.1073/pnas.1420833112. View

Zeng X, Chen L, Jost C, Maya R, Keller D, Wang X . MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999; 19(5):3257-66. PMC: 84120. DOI: 10.1128/MCB.19.5.3257. View

10.

Chen L, Li C, Pan Y, Chen J . Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol. 2005; 25(15):6509-20. PMC: 1190343. DOI: 10.1128/MCB.25.15.6509-6520.2005. View

11.

Wang X, Arooz T, Siu W, Chiu C, Lau A, Yamashita K . MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett. 2001; 490(3):202-8. DOI: 10.1016/s0014-5793(01)02124-x. View

12.

Grier J, Yan W, Lozano G . Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis. 2002; 32(2):145-7. DOI: 10.1002/gene.10066. View

13.

Dobbelstein M, Wienzek S, Konig C, Roth J . Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene. 1999; 18(12):2101-6. DOI: 10.1038/sj.onc.1202512. View

14.

Bottger V, Bottger A, Garcia-Echeverria C, Ramos Y, Van Der Eb A, Jochemsen A . Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene. 1999; 18(1):189-99. DOI: 10.1038/sj.onc.1202281. View

15.

Chauhan D, Tian Z, Nicholson B, Kumar K, Zhou B, Carrasco R . A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012; 22(3):345-58. PMC: 3478134. DOI: 10.1016/j.ccr.2012.08.007. View

16.

Gembarska A, Luciani F, Fedele C, Russell E, Dewaele M, Villar S . MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012; 18(8):1239-47. PMC: 3744207. DOI: 10.1038/nm.2863. View

17.

Dal Bo M, Secchiero P, Degan M, Marconi D, Bomben R, Pozzato G . MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. Br J Haematol. 2010; 150(2):237-9. DOI: 10.1111/j.1365-2141.2010.08185.x. View

18.

Wu H, Leng R . MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function. Oncotarget. 2015; 6(25):21479-92. PMC: 4673280. DOI: 10.18632/oncotarget.4086. View

19.

Shvarts A, Steegenga W, Riteco N, van Laar T, Dekker P, Bazuine M . MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996; 15(19):5349-57. PMC: 452278. View

20.

Hsieh J, Chan F, OConnor D, Mittnacht S, Zhong S, Lu X . RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell. 1999; 3(2):181-93. DOI: 10.1016/s1097-2765(00)80309-3. View